Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other Non-Current Liabilities (2021 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities rose 3.91% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Sep 2025, up 3.91%, and an annual FY2024 reading of $2.6 million, up 100.0% over the prior year.
  • Other Non-Current Liabilities was $1.5 million for Q3 2025 at Barinthus Biotherapeutics, down from $2.5 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $2.6 million in Q4 2024 and bottomed at $434000.0 in Q1 2022.
  • Average Other Non-Current Liabilities over 5 years is $1.6 million, with a median of $1.6 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities soared 294.01% in 2023, then tumbled 36.8% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $2.4 million in 2021, then dropped by 27.84% to $1.7 million in 2022, then decreased by 22.56% to $1.3 million in 2023, then skyrocketed by 100.0% to $2.6 million in 2024, then crashed by 44.87% to $1.5 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for BRNS at $1.5 million in Q3 2025, $2.5 million in Q2 2025, and $1.4 million in Q1 2025.